Skip to main content

Table 1 Demographics and baseline characteristics of the participants

From: Efficacy and safety of fixed dose combination of Sitagliptin, metformin, and pioglitazone in type 2 Diabetes (IMPACT study): a randomized controlled trial

Characteristics

FDC of MSP (N = 118)

MS (N = 118)

P value

Male, n (%)

62 (52.5%)

63 (53.4%)

0.43

Female, n (%)

56 (47.5%)

55 (46.6%)

0.37

Age, years, mean (SD)

51.7 (8.01)

49.6 (9.54)

0.0787

Weight, kg, mean (SD)

67.1 (12.87)

65.5 (10.94)

0.3074

Height, cm, mean (SD)

162.8 (8.23)

161.5 (7.79)

0.2081

BMI, kg/m2, mean (SD)

25.2 (3.81)

25.1 (3.55)

0.772

Waist circumference, inches, mean (SD)

36.8 (3.62)

36.2 (3.68)

0.2106

Waist-to-hip ratio, mean (SD)

0.9 (0.07)

0.9 (0.10)

0.3733

HbA1C, %, mean (SD)

9.21 (0.78)

9.25 (0.78)

0.7181

Duration of diabetes, months, mean (SD), range

41.1 (33.47), 2–169.4

36.5 (42.86), 1.5–360.6

0.3524

  1. FDC of MSP, fixed-dose combination of metformin, sitagliptin, and pioglitazone, MS, FDC of metformin and sitagliptin, SD standard deviation